<p>WBH Advisory Inc. 在最近向证券交易委员会提交的 13F 表格中表示，在第一季度将其在礼来的股份减少了 6.4%。该机构投资者在此期间出售了 574 股后，持有该公司 8,400 股股票。截至其最近向证券交易委员会提交的文件，WBH Advisory Inc. 在礼来的持股价值为 6,938,000 美元。</p>
<p>获取 <strong>礼来</strong> 的提醒：</p>
<ul>
<li>特朗普 GLP-1 试点计划可能推动诺和诺德和礼来的增长</li>
</ul>
<p>其他一些对冲基金和机构投资者最近也对该公司的持仓进行了调整。Garner Asset Management Corp 在第四季度将其在礼来的持仓提高了 2.3%。Garner Asset Management Corp 目前持有 532 股该公司的股票，价值 411,000 美元，此前在上个季度增持了 12 股。Tobias Financial Advisors Inc. 在第四季度将其在礼来的股份提高了 4.1%。Tobias Financial Advisors Inc. 目前持有 307 股该公司的股票，价值 237,000 美元，此前在上个季度增持了 12 股。Redwood Investments LLC 在第四季度将其在礼来的持股提高了 0.5%。Redwood Investments LLC 目前持有 2,209 股该公司的股票，价值 1,705,000 美元，此前在上个季度增持了 12 股。Hobbs Wealth Management LLC 在第一季度将其在礼来的持仓提高了 0.8%。Hobbs Wealth Management LLC 目前持有 1,459 股该公司的股票，价值 1,205,000 美元，此前在此期间增持了 12 股。最后，Hixon Zuercher LLC 在第一季度将其在礼来的持股提高了 0.7%。Hixon Zuercher LLC 目前持有 1,789 股该公司的股票，价值 1,477,000 美元，此前在上个季度增持了 12 股。82.53% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>礼来股票下跌 14.2%</h2>
<p>礼来股票周五开盘价为 640.17 美元。该公司的 50 日移动平均价格为 776.36 美元，200 日移动平均价格为 799.60 美元。礼来公司的 12 个月低点为 633.20 美元，12 个月高点为 972.53 美元。该公司的流动比率为 1.37，速动比率为 1.06，债务与股本比率为 2.18。该股票的市值为 6067.1 亿美元，市盈率为 52.09，市盈增长比率为 1.06，贝塔值为 0.44。</p>
<ul>
<li>诺和诺德股票下跌——但是否终于触底？</li>
</ul>
<p>礼来公司（NYSE:LLY - 获取免费报告）最近在 8 月 7 日星期四公布了季度财报。该公司报告每股收益（EPS）为 6.31 美元，超出市场共识预期的 5.59 美元，超出 0.72 美元。该公司在本季度的收入为 155.6 亿美元，而分析师预期为 144.0 亿美元。礼来公司的净利润率为 22.67%，股本回报率为 85.51%。该公司的收入同比增长 37.6%。在去年同期，该公司每股收益为 3.92 美元。整体来看，股票研究分析师预计礼来公司在当前财年将发布 23.48 美元的每股收益。</p>
<h2>礼来公司分红公告</h2>
<p>该公司还最近宣布了一项季度分红，将于 9 月 10 日星期三支付。8 月 15 日星期五的登记投资者将获得每股 1.50 美元的分红。除息日为 8 月 15 日星期五。这代表着每年 6.00 美元的分红和 0.9% 的分红收益率。礼来公司的分红支付比率目前为 48.82%。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>医疗保健股票估值触底，3 个名字有望反弹</li>
</ul>
<p>礼来股票已成为几份研究报告的主题。富国银行在 5 月 1 日星期四的研究报告中重申了对礼来股票的 “增持” 评级。摩根士丹利在 7 月 10 日星期四的研究报告中重申了 “增持” 评级，并将礼来股票的目标价从 1,133.00 美元上调至 1,135.00 美元。Leerink Partners 在一份报告中重申了 “市场表现” 评级，并将礼来股票的目标价定为 715.00 美元。华尔街 Zen 在 7 月 26 日星期六的报告中将礼来公司从 “持有” 评级上调至 “买入” 评级。最后，Guggenheim 将礼来公司的目标价从 936.00 美元上调至 942.00 美元，并在 7 月 11 日星期五的报告中给予该股票 “买入” 评级。一位分析师对该股票给予了卖出评级，四位给予了持有评级，十七位给予了买入评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 999.50 美元。</p>
<p><strong>获取我们关于礼来的最新报告</strong></p>
<h2>关于礼来公司</h2>
<p>（免费报告）</p>
<p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
<h2>进一步阅读</h2>
<ul>
<li>五只我们更看好的股票，胜过礼来公司</li>
<li>Roth IRA 计算器：计算您的潜在回报</li>
<li>为什么单片电源的收益和指引引发了市场反弹</li>
<li>3 只家居改善股票可以升级您的投资组合</li>
<li>AppLovin 第二季度业绩不佳让市场紧张，但华尔街加倍下注</li>
<li>如何开始投资房地产</li>
<li>微软股票上涨，分析师提高目标价</li>
</ul>
<p><strong>想知道其他对 LLY 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 Eli Lilly and Company (NYSE:LLY - 免费报告) 的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Eli Lilly and Company 吗？</h2>
<p>在考虑 Eli Lilly and Company 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Eli Lilly and Company 并不在名单上。</p>
<p>虽然 Eli Lilly and Company 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>WBH Advisory Inc. 在第一季度减少了对礼来的持股比例，降幅为 6.4%，目前持有 8,400 股，价值约为 694 万美元。其他机构投资者也调整了他们的持仓，其中 82.53% 的股票由这些实体持有。礼来的股票价格下跌了 14.2%，当前价格为 640.17 美元。该公司报告了强劲的收益，每股收益为 6.31 美元，超出预期，并宣布每股季度分红为 1.50 美元</p>

<p>WBH Advisory Inc. trimmed its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 6.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,400 shares of the company's stock after selling 574 shares during the period. WBH Advisory Inc.'s holdings in Eli Lilly and Company were worth $6,938,000 as of its most recent filing with the Securities and Exchange Commission.</p>
<div class="lb-trans"><p>WBH Advisory Inc. 在最近向证券交易委员会提交的 13F 表格中表示，在第一季度将其在礼来的股份减少了 6.4%。该机构投资者在此期间出售了 574 股后，持有该公司 8,400 股股票。截至其最近向证券交易委员会提交的文件，WBH Advisory Inc. 在礼来的持股价值为 6,938,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来</strong> 的提醒：</p>
</div><ul>
<li>Trump GLP-1 Pilot Program Could Boost Novo Nordisk &amp; Eli Lilly</li>
</ul>
<div class="lb-trans"><ul>
<li>特朗普 GLP-1 试点计划可能推动诺和诺德和礼来的增长</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. Garner Asset Management Corp lifted its position in Eli Lilly and Company by 2.3% during the 4th quarter. Garner Asset Management Corp now owns 532 shares of the company's stock worth $411,000 after acquiring an additional 12 shares during the last quarter. Tobias Financial Advisors Inc. boosted its position in shares of Eli Lilly and Company by 4.1% during the 4th quarter. Tobias Financial Advisors Inc. now owns 307 shares of the company's stock valued at $237,000 after acquiring an additional 12 shares in the last quarter. Redwood Investments LLC boosted its holdings in Eli Lilly and Company by 0.5% during the fourth quarter. Redwood Investments LLC now owns 2,209 shares of the company's stock valued at $1,705,000 after purchasing an additional 12 shares in the last quarter. Hobbs Wealth Management LLC grew its position in Eli Lilly and Company by 0.8% in the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after acquiring an additional 12 shares during the period. Finally, Hixon Zuercher LLC grew its holdings in shares of Eli Lilly and Company by 0.7% in the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock worth $1,477,000 after purchasing an additional 12 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者最近也对该公司的持仓进行了调整。Garner Asset Management Corp 在第四季度将其在礼来的持仓提高了 2.3%。Garner Asset Management Corp 目前持有 532 股该公司的股票，价值 411,000 美元，此前在上个季度增持了 12 股。Tobias Financial Advisors Inc. 在第四季度将其在礼来的股份提高了 4.1%。Tobias Financial Advisors Inc. 目前持有 307 股该公司的股票，价值 237,000 美元，此前在上个季度增持了 12 股。Redwood Investments LLC 在第四季度将其在礼来的持股提高了 0.5%。Redwood Investments LLC 目前持有 2,209 股该公司的股票，价值 1,705,000 美元，此前在上个季度增持了 12 股。Hobbs Wealth Management LLC 在第一季度将其在礼来的持仓提高了 0.8%。Hobbs Wealth Management LLC 目前持有 1,459 股该公司的股票，价值 1,205,000 美元，此前在此期间增持了 12 股。最后，Hixon Zuercher LLC 在第一季度将其在礼来的持股提高了 0.7%。Hixon Zuercher LLC 目前持有 1,789 股该公司的股票，价值 1,477,000 美元，此前在上个季度增持了 12 股。82.53% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Eli Lilly and Company Stock Down 14.2%</h2>
<div class="lb-trans"><h2>礼来股票下跌 14.2%</h2>
</div><p>LLY stock opened at $640.17 on Friday. The firm has a 50-day moving average price of $776.36 and a 200-day moving average price of $799.60. Eli Lilly and Company has a 12 month low of $633.20 and a 12 month high of $972.53. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The stock has a market capitalization of $606.71 billion, a P/E ratio of 52.09, a price-to-earnings-growth ratio of 1.06 and a beta of 0.44.</p>
<div class="lb-trans"><p>礼来股票周五开盘价为 640.17 美元。该公司的 50 日移动平均价格为 776.36 美元，200 日移动平均价格为 799.60 美元。礼来公司的 12 个月低点为 633.20 美元，12 个月高点为 972.53 美元。该公司的流动比率为 1.37，速动比率为 1.06，债务与股本比率为 2.18。该股票的市值为 6067.1 亿美元，市盈率为 52.09，市盈增长比率为 1.06，贝塔值为 0.44。</p>
</div><ul>
<li>Novo Nordisk Stock Sinks—But Is a Bottom Finally In?</li>
</ul>
<div class="lb-trans"><ul>
<li>诺和诺德股票下跌——但是否终于触底？</li>
</ul>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The company's revenue was up 37.6% on a year-over-year basis. During the same period in the prior year, the company posted $3.92 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最近在 8 月 7 日星期四公布了季度财报。该公司报告每股收益（EPS）为 6.31 美元，超出市场共识预期的 5.59 美元，超出 0.72 美元。该公司在本季度的收入为 155.6 亿美元，而分析师预期为 144.0 亿美元。礼来公司的净利润率为 22.67%，股本回报率为 85.51%。该公司的收入同比增长 37.6%。在去年同期，该公司每股收益为 3.92 美元。整体来看，股票研究分析师预计礼来公司在当前财年将发布 23.48 美元的每股收益。</p>
</div><h2>Eli Lilly and Company Dividend Announcement</h2>
<div class="lb-trans"><h2>礼来公司分红公告</h2>
</div><p>The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be given a dividend of $1.50 per share. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a dividend yield of 0.9%. Eli Lilly and Company's dividend payout ratio is presently 48.82%.</p>
<div class="lb-trans"><p>该公司还最近宣布了一项季度分红，将于 9 月 10 日星期三支付。8 月 15 日星期五的登记投资者将获得每股 1.50 美元的分红。除息日为 8 月 15 日星期五。这代表着每年 6.00 美元的分红和 0.9% 的分红收益率。礼来公司的分红支付比率目前为 48.82%。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Healthcare Stocks Hit Valuation Bottom, 3 Names to Rebound</li>
</ul>
<div class="lb-trans"><ul>
<li>医疗保健股票估值触底，3 个名字有望反弹</li>
</ul>
</div><p>LLY has been the topic of several research reports. Wells Fargo &amp; Company reiterated an &#34;overweight&#34; rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Morgan Stanley restated an &#34;overweight&#34; rating and issued a $1,135.00 price objective (up previously from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday, July 10th. Leerink Partners restated a &#34;market perform&#34; rating and set a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday. Wall Street Zen upgraded Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday, July 26th. Finally, Guggenheim increased their target price on shares of Eli Lilly and Company from $936.00 to $942.00 and gave the stock a &#34;buy&#34; rating in a report on Friday, July 11th. One analyst has rated the stock with a sell rating, four have given a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of &#34;Moderate Buy&#34; and an average target price of $999.50.</p>
<div class="lb-trans"><p>礼来股票已成为几份研究报告的主题。富国银行在 5 月 1 日星期四的研究报告中重申了对礼来股票的 “增持” 评级。摩根士丹利在 7 月 10 日星期四的研究报告中重申了 “增持” 评级，并将礼来股票的目标价从 1,133.00 美元上调至 1,135.00 美元。Leerink Partners 在一份报告中重申了 “市场表现” 评级，并将礼来股票的目标价定为 715.00 美元。华尔街 Zen 在 7 月 26 日星期六的报告中将礼来公司从 “持有” 评级上调至 “买入” 评级。最后，Guggenheim 将礼来公司的目标价从 936.00 美元上调至 942.00 美元，并在 7 月 11 日星期五的报告中给予该股票 “买入” 评级。一位分析师对该股票给予了卖出评级，四位给予了持有评级，十七位给予了买入评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，平均目标价为 999.50 美元。</p>
</div><p><strong>Get Our Latest Report on LLY</strong></p>
<div class="lb-trans"><p><strong>获取我们关于礼来的最新报告</strong></p>
</div><h2>About Eli Lilly and Company</h2>
<div class="lb-trans"><h2>关于礼来公司</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p>
<div class="lb-trans"><p>礼来公司在全球范围内发现、开发和销售人用药物。该公司提供 Basaglar、Humalog、Humalog Mix 75/25、Humalog U-100、Humalog U-200、Humalog Mix 50/50、胰岛素利普罗、胰岛素利普罗原料、胰岛素利普罗混合 75/25、Humulin、Humulin 70/30、Humulin N、Humulin R 和 Humulin U-500 用于糖尿病；Jardiance、Mounjaro 和 Trulicity 用于 2 型糖尿病；以及 Zepbound 用于肥胖。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>Roth IRA Calculator: Calculate Your Potential Returns</li>
<li>Why Monolithic Power's Earnings and Guidance Ignited a Rally</li>
<li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li>
<li>AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down</li>
<li>How to Start Investing in Real Estate</li>
<li>Microsoft Stock Gains as Analysts Boost Price Targets</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过礼来公司</li>
<li>Roth IRA 计算器：计算您的潜在回报</li>
<li>为什么单片电源的收益和指引引发了市场反弹</li>
<li>3 只家居改善股票可以升级您的投资组合</li>
<li>AppLovin 第二季度业绩不佳让市场紧张，但华尔街加倍下注</li>
<li>如何开始投资房地产</li>
<li>微软股票上涨，分析师提高目标价</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding LLY?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 LLY 持有的对冲基金吗？</strong> 请访问 HoldingsChannel.com 获取 Eli Lilly and Company (NYSE:LLY - 免费报告) 的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Eli Lilly and Company 吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Eli Lilly and Company 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Eli Lilly and Company 并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Eli Lilly and Company 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

WBH Advisory Inc. 在礼来公司（NYSE:LLY）中持有价值 694 万美元的股份